Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeting of Glutamine Pathways Restores Sensitivity in Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Jessica T Leonard, MD, Bill H. Chang, MD PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Marc Loriaux, MD PhD, Pavani Malla, MS

Blood (2017) 130 (Supplement 1): 1264.

https://doi.org/10.1182/blood.V130.Suppl_1.1264.1264

Published: 2017

Journal Articles

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Stephen E Spurgeon, MD, Rachel Cook, MD MS, Elie Traer, MD, Uma Borate, MD, Richard T. Maziarz, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Tara Macey, PhD, Kristen Werth, Brian Junio, Cristina E. Tognon, Motomi Mori, PhD, Marc Loriaux, MD PhD

Blood (2016) 128 (22): 4051.

https://doi.org/10.1182/blood.V128.22.4051.4051

Published: 2016

Journal Articles

p38MAPK Inhibition Blocks Inflammatory Signaling in Acute Myeloid Leukemia

Alyssa Carey, B.S., Swati Garg, Megan M Cleary, B.S., B.A., David K Edwards, V, B.A., B.S., Marc Loriaux, MD PhD, Shannon L Winski, PhD, LouAnn Cable, B.S., Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 2603.

https://doi.org/10.1182/blood.V126.23.2603.2603

Published: 2015

Journal Articles

Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

Tyler Sweeney, Stephen E Spurgeon, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD, Hibery Ho, Elie Traer, MD PhD, Patrice Lee, PhD, David Chantry, PhD, Brian J. Druker, MD, Marc Loriaux, MD PhD

Blood (2015) 126 (23): 4439.

https://doi.org/10.1182/blood.V126.23.4439.4439

Published: 2015

Journal Articles

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

David K Edwards, V, B.A., B.S., Angela Rofelty, BS, Anupriya Agarwal, PhD, Stephen E Kurtz, PhD, Elie Traer, MD PhD, Patrice Lee, PhD, David Chantry, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 3824.

https://doi.org/10.1182/blood.V126.23.3824.3824

Published: 2015

Journal Articles

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Jessica Leonard, MD, Joelle Rowley, Brandon Hayes-Lattin, MD, Jeffrey W. Tyner, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Bill H Chang, MD PhD

Blood (2015) 126 (23): 1329.

https://doi.org/10.1182/blood.V126.23.1329.1329

Published: 2015

Journal Articles

Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

Adam Lamble, MD, Yoko Kosaka, PhD, Pierrette Lo, MS, Fei Huang, PhD, Kate Sasser, PhD, Cristina E. Tognon, PhD, Marc Loriaux, MD PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Evan F. Lind, PhD

Blood (2015) 126 (23): 1374.

https://doi.org/10.1182/blood.V126.23.1374.1374

Published: 2015

Journal Articles

A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Emma C. Scott, MD, Dan T. Vogl, MD MSCE, Shara Reasor-Heard, Kevin Floyd, Eva Medvedova, MD, Stephen E. Spurgeon, MD, Miranda Gordon, RN, Anne Kratz, RN, Matthew B. Siegel, MD, Marc Loriaux, MD PhD, Phoebe Trubowitz, MD, Stephen D Smith, MD, Selina Qiuying Liu, Ranjana Arora, MD, Edward A. Stadtmauer, Ravi K. Amaravadi, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3449.

https://doi.org/10.1182/blood.V124.21.3449.3449

Published: 2014

Journal Articles

Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis.

Jeffrey W Tyner, PhD, Luke Fletcher, Wayne Yang, Stephen T Oh, MD, PhD, Jason R. Gotlib, MD, Michael WN Deininger, MD, Brian J. Druker, MD, Marc Loriaux, MD, PhD

Blood (2009) 114 (22): 708.

https://doi.org/10.1182/blood.V114.22.708.708

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill H Chang, MD, PhD, Vincent T Bicocca, Stephen T Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. DenBoer, MSc, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Jason R Gotlib, MD, MS, Michael Deininger, MD, PhD, Brian J. Druker, MD

Blood (2009) 114 (22): 3978.

https://doi.org/10.1182/blood.V114.22.3978.3978

Published: 2009

Journal Articles

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Jeffrey W Tyner, PhD, Heidi Erickson, Stephen Oh, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker, Marc Loriaux, MD, PhD

Blood (2008) 112 (11): 2519.

https://doi.org/10.1182/blood.V112.11.2519.2519

Published: 2008

Journal Articles

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill Chang, MD, PhD, Vincent T Bicocca, Stephen Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. den Boer, C. M Zwaan, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker

Blood (2008) 112 (11): 758.

https://doi.org/10.1182/blood.V112.11.758.758

Published: 2008

Journal Articles

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Thomas G.P. Bumm, MD, Jonathan VanDyke, Marc Loriaux, MD, PhD, Carolyn Gendron, Lisa G. Wood, PhD, RN, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2007) 110 (11): 675.

https://doi.org/10.1182/blood.V110.11.675.675

Published: 2007

Journal Articles

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Anupriya Agarwal, PhD, Thomas G.P. Bumm, MD, Amie Corbin, Thomas O’Hare, PhD, Marc Loriaux, MD, PhD, Stephanie G. Willis, Jutta Deininger, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 742.

https://doi.org/10.1182/blood.V108.11.742.742

Published: 2006

Journal Articles

JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.

Thomas G.P. Bumm, MD, Collin Elsea, Lisa G. Wood, RN, PhD, Daniel W. Sherbenou, Ian J. Griswold, PhD, Marc Loriaux, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 376.

https://doi.org/10.1182/blood.V106.11.376.376

Published: 2005

NARROW

Targeting of Glutamine Pathways Restores Sensitivity in Venetoclax Resistant Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

p38MAPK Inhibition Blocks Inflammatory Signaling in Acute Myeloid Leukemia

Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia

A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma

Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only